According to Astanehe et al., MKNK1 could mediate targeted drug resistance in HER2‐positive breast cancer, and its expression downregulation by siRNA can increase the cancer cells' sensitivity to trastuzumab.49 The gene discussed is ERBB2; the disease is breast carcinoma.